Crude and adjusted ORs and 95% CIs for the association between clinical outcomes and serum albumin level according to duration of UC
| Variable | Prevalence (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
| Duration of UC <7 years (n=129) | |||
| Clinical remission | |||
| Low albumin | 14/38 (36.8) | 1 | 1 |
| Moderate albumin | 25/48 (52.1) | 1.86 (0.79 to 4.51) | 1.79 (0.58 to 5.05) |
| High albumin | 26/43 (60.5) | 2.62 (1.08 to 6.57) | 3.65 (1.05 to 13.66) |
| p for trend | 0.03 | ||
| Partial mucosal healing (MES ≤1) | |||
| Low albumin | 18/38 (39.5) | 1 | 1 |
| Moderate albumin | 30/48 (62.5) | 2.55 (1.08 to 6.24) | 1.56 (0.52 to 4.74) |
| High albumin | 29/43 (67.4) | 3.17 (1.30 to 8.09) | 1.91 (0.58 to 6.44) |
| p for trend | 0.30 | ||
| Mucosal healing (MES=0) | |||
| Low albumin | 5/38 (13.2) | 1 | 1 |
| Moderate albumin | 8/48 (16.7) | 1.32 (0.40 to 4.73) | 1.58 (0.39 to 6.97) |
| High albumin | 14/43 (32.6) | 3.19 (1.08 to 10.85) | 6.85 (1.54 to 36.45) |
| p for trend | 0.005 | ||
| Duration of UC ≥7 years (n=144) | 0.021 | ||
| Clinical remission | |||
| Low albumin | 34/55 (61.8) | 1 | 1 |
| Moderate albumin | 35/50 (70) | 1.44 (0.64 to 3.29) | 0.97 (0.37 to 2.50) |
| High albumin | 24/39 (61.5) | 0.99 (0.43 to 2.32) | 0.68 (0.24 to 1.85) |
| p for trend | 0.46 | ||
| Partial mucosal healing (MES ≤1) | |||
| Low albumin | 36/55 (65.5) | 1 | 1 |
| Moderate albumin | 37/50 (74) | 1.50 (0.65 to 3.54) | 1.07 (0.41 to 2.82) |
| High albumin | 25/39 (64.1) | 0.94 (0.40 to 2.25) | 0.64 (0.23 to 1.76) |
| p for trend | 0.42 | ||
| Mucosal healing (MES=0) | |||
| Low albumin | 13/55 (23.6) | 1 | 1 |
| Moderate albumin | 19/50 (38) | 1.98 (0.86 to 4.69) | 1.75 (0.69 to 4.58) |
| High albumin | 12/39 (30.8) | 1.44 (0.57 to 3.63) | 1.27 (0.45 to 3.63) |
| p for trend | 0.63 |
ORs were adjusted for age, sex, body mass index, use of prednisolone, use of tumour necrosis factor-α monoclonal antibody, C reactive protein, and disease extent.
MES, Mayo endoscopic subscore; UC, ulcerative colitis.